文献速递其他结缔组织病血管炎

系统性硬化症中的ANCA:当血管炎与血管病变重叠时的致命组合

ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本文综述了系统性硬化症(SSc)患者中ANCA相关性血管炎(SSc-AAV)共存的临床特点与诊治挑战。SSc患者中ANCA并不少见,以p-ANCA和抗髓过氧化物酶抗体最常见,常表现为显微镜下多血管炎或肾局限性血管炎,病情严重。目前SSc-AAV多按孤立性AAV治疗,但大剂量激素可能诱发硬皮病肾危象,需警惕。

要点

  • SSc患者应警惕ANCA阳性,尤其p-ANCA和抗MPO抗体,提示可能合并AAV。
  • SSc-AAV常累及肺和肾,病情重,需与SSc本身器官受累鉴别。
  • 治疗参照孤立性AAV但需警惕大剂量激素诱发硬皮病肾危象。

核心结论

  • SSc与ANCA相关性血管炎共存(SSc-AAV)与严重疾病进程相关,包括显著的肺和肾受累。
  • SSc-AAV通常按孤立性AAV治疗,但大剂量激素在SSc患者中可能诱发硬皮病肾危象,存在潜在风险。
  • SSc-AAV是一种罕见临床实体,亟需严谨研究以定义治疗策略。

研究设计与样本

  • 本文为综述,基于文献汇总分析SSc-AAV的临床特点、发病机制及诊疗现状。

主要发现

  • SSc患者中ANCA并不少见,p-ANCA和抗髓过氧化物酶抗体是最常见的抗体。
  • SSc-AAV患者通常表现为显微镜下多血管炎或肾局限性血管炎的临床特征。
  • SSc和AAV在发病机制上存在多个潜在交互领域,可能加重血管病变。
  • 两种疾病均可出现相似的Major内部器官受累模式(如肺和肾)。

关键数值与推荐

  • p-ANCA和抗髓过氧化物酶抗体是SSc-AAV中最常见的抗体类型。
  • SSc-AAV的典型临床表现为显微镜下多血管炎或肾局限性血管炎。

临床怎么用

  • 临床医生对SSc患者应保持高度临床怀疑以识别SSc-AAV。
  • SSc-AAV的治疗目前参照孤立性AAV,但需警惕大剂量激素与硬皮病肾危象的关联。
  • 需进一步研究以定义SSc-AAV的治疗策略,改善这一致命组合的预后。

局限性

  • 目前缺乏数据指导SSc-AAV的管理,治疗策略多沿用孤立性AAV的经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with SSc, the coexistence of ANCA-associated vasculitis (SSc-AAV) has been reported to be associated with a severe disease course, including significant pulmonary and renal involvement. The presence of ANCA is not uncommon in patients with SSc, and therefore clinicians must maintain a high index of clinical suspicion about SSc-AAV. p-ANCA and anti-myeloperoxidase antibodies are the most common antibodies observed. Patients typically present with clinical features of microscopic polyangiitis or renal-limited vasculitis. There are multiple areas of potential interaction in the pathogenesis of SSc and AAV, which can exacerbate/compound vascular disease. In addition, similar patterns of major internal organ involvement (e.g. lung and kidneys) are seen in both conditions. We highlight a diagnostic approach to SSc-AAV and the paucity of data to inform management. As such, SSc-AAV is typically treated as per isolated AAV, which can potentially be hazardous in patients with SSc (e.g. due to the association between high-dose steroid and scleroderma renal crisis). We propose that this rare clinical entity warrants rigorous investigation, including definition of a therapeutic strategy to ameliorate the potentially devastating combination of pathologies in SSc-AAV.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hughes M, Kahaleh B, Denton CP, et al. ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. Rheumatology (Oxford). 2021. PMID: 33744916. doi:10.1093/rheumatology/keab278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。